CD8A and neoplasm: After multivariate correction, high tumor IL6 (>median) was associated significantly with poor overall survival (OS) only in patients who received atezolizumab monotherapy (hazard ratio [HR]: 2.72, 95% confidence interval [CI]: 1.30, 5.72, p = 0.008; Figure 1E), including those with high expression of a CD8+ T cell signature (HR: 4.30, 95% CI: 1.35, 13.71, p = 0.014; Figure 1F).11